Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D.
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411
Doi: 10.1002/cncr.23722
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND. Dacarbazine (DTIC) and pegylated interferon (IFN)-alpha-2a have both demonstrated some efficacy as single agents in metastatic melanoma. To the authors' knowledge, the current study is the first to test a combination of these 2 agents in a phase 2 trial. METHODS. Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 mu g. The study was initiated to evaluate the efficacy and tolerability of the combination. The primary study end-point was objective response. RESULTS. Twenty-five patients were evaluable for response. Two patients (8.0%) achieved a complete response that continued for >480 days and 746 days, respectively. Four patients (16.0%) demonstrated a partial response, and another patient experienced stable disease. Six of 7 nonprogressive patients had either not received treatment or had not developed disease progression during adjuvant IFN treatment for stage II/III disease. The median duration of response was 236 days, the median progression-free survival was 56 days, and the overall survival time was 403 days. Few grade 3 toxicities and only 1 grade 4 toxicity were observed (according to National Cancer Institute Common Toxicity Criteria). CONCLUSIONS. The combination of DTIC and pegylated IFN-alpha-2a was found to be well tolerated in patients with metastatic melanoma. The response rate of 24%, including 2 long-lasting complete responses, is encouraging, but must be confirmed in larger trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Agents, Alkylating - therapeutic use
- Antiviral Agents - therapeutic use
- Bone Neoplasms - drug therapy Bone Neoplasms - secondary
- Dacarbazine - therapeutic use
- Drug Carriers -
- Drug Therapy, Combination -
- Female -
- Humans -
- Interferon Alfa-2a - therapeutic use
- Liver Neoplasms - drug therapy Liver Neoplasms - secondary
- Lung Neoplasms - drug therapy Lung Neoplasms - secondary
- Lymphatic Metastasis -
- Male -
- Melanoma - drug therapy Melanoma - pathology
- Middle Aged -
- Neoplasm Staging -
- Polyethylene Glycols - therapeutic use
- Prognosis -
- Prospective Studies -
- Survival Rate -
- Find related publications in this database (Keywords)
- dacarbazine
- pegylated interferon-alpha-2a
- metastatic melanoma
- response
- survival